A Phase 1 Single Ascending Dose Study of the Novel GLP-1R Agonist GL0034 in Subjects With Obesity

被引：0
|
作者：
Thennati, Rajamannar
Burade, Vinod
Natarajan, Muthukumar
Shahi, Pradeep
Nagaraja, Ravishankara
Panchal, Satish
Agrawal, Sudeep
Jandrain, Bernard
Duvauchelle, Thierry
Pratley, Richard
Thorens, Bernard
Vilsboll, Tina
机构：
来源：
OBESITY | 2023年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
577
引用
收藏
页码：284 / 284
页数：1
相关论文
共 50 条
  • [31] Maleimide based tethering of a potential tripeptide agonist to GLP-1R
    Buglione-Corbett, Rachel
    Scobee, Meghan B.
    Haines, David R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 697 - 697
  • [32] GLP-1R agonist therapy for diabetes: benefits and potential risks
    Samson, Susan L.
    Garber, Alan
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2013, 20 (02) : 87 - 97
  • [33] A novel long-acting GLP-1 agonist (GL0034) demonstrates remarkable efficacy on HbA1c, weight loss and triglycerides in a model of type 2 diabetes, the db/db mouse
    Anholm, C.
    Kumarathurai, P.
    Skytte, M. G. J.
    Nielsen, O. W.
    Kristiansen, O. P.
    Barker, P.
    Burling, K.
    Fenger, M.
    Madsbad, S.
    Sajadieh, A.
    Haugaard, S. B.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S279 - S280
  • [34] Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist
    Lear, Sam
    Seo, Hyosuk
    Lee, Candy
    Lei, Lei
    Amso, Zaid
    Huang, David
    Zou, Huafei
    Zhou, Zhihong
    Nguyen-Tran, Van T. B.
    Shen, Weijun
    MOLECULES, 2020, 25 (11):
  • [35] A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity
    Ding, Ke
    DIABETES, 2024, 73
  • [36] GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors
    Shilyansky, Jonathan S.
    Chan, Casandro J.
    Xiao, Sophia
    Gribovskaja-Rupp, Irena
    Quelle, Dawn E.
    Howe, James R.
    Dillon, Joseph S.
    Ear, Po Hien
    SURGERY, 2025, 179
  • [37] GLP-1R AGONISTS AND WEIGHT LOSS Utility of GLP-1R agonists in diabetes requires long term study
    Franco de Oliveira, Jose Mario
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [38] Pharmacokinetics and Pharmacodynamic Effects of a Single Dose of the Long-Acting GLP-1R Agonist LAPS-Exendin-4 in Subjects With Type 2 Diabetes Mellitus
    Kim, Yung I.
    Kim, Sei-Eun
    Choi, In Young
    Bae, Sungmin
    Lee, Kyu Hwang
    Park, Kyung-Mi
    Kang, Jahoon
    Kwon, Se Chang
    Son, Jeewoong
    DIABETES, 2012, 61 : A277 - A277
  • [39] BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
    Zimmermann, Tina
    Thomas, Leo
    Baader-Pagler, Tamara
    Haebel, Peter
    Simon, Eric
    Reindl, Wolfgang
    Bajrami, Besnik
    Rist, Wolfgang
    Uphues, Ingo
    Drucker, Daniel J.
    Klein, Holger
    Santhanam, Rakesh
    Hamprecht, Dieter
    Neubauer, Heike
    Augustin, Robert
    MOLECULAR METABOLISM, 2022, 66
  • [40] HEMODYNAMIC EFFECT OF A SINGLE DOSE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) AGONIST LIRAGLUTIDE IN PATIENTS WITH DIABETIC KIDNEY DISEASE
    Wajdlich, M.
    Nowicki, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (05): : 751 - 761
12345